Status:
COMPLETED
Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine
Lead Sponsor:
GlaxoSmithKline
Conditions:
Malaria
Eligibility:
All Genders
33-69 years
Phase:
PHASE2
Brief Summary
The RTS,S/AS02A vaccine (or GSK 257049 vaccine), GSK Biologicals' candidate Plasmodium falciparum (P. falciparum) malaria vaccine is being developed for the routine immunization of infants and childre...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Completion of Visit 7, Month 21 of 104297 (NCT= NCT00197041).
- Written informed consent obtained from the parent(s) or guardian(s) of the subject
- Exclusion criteria:
- Planned use of any investigational or non-registered drug or vaccine during the study period.
- Simultaneous participation in any other clinical trial
Exclusion
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
1737 Patients enrolled
Trial Details
Trial ID
NCT00323622
Start Date
April 1 2005
End Date
May 1 2007
Last Update
December 9 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Maputo, Mozambique